Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Food and Drug Administration

Johnson & Johnson
Regional

Johnson & Johnson Seeks FDA Approval for New Ulcerative Colitis Treatment

March 20, 2024March 19, 2024 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson announced it recently submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for TREMFYA® (guselkumab). This application …

Johnson & Johnson Seeks FDA Approval for New Ulcerative Colitis Treatment Read More

Optinose
Regional

FDA Approves Optinose’s XHANCE as First Treatment for Sinusitis Without Nasal Polyps

March 19, 2024March 19, 2024 - by Timothy Alexander

YARDLEY, PA — The U.S. Food and Drug Administration (FDA) recently approved XHANCE® (fluticasone propionate) nasal spray, developed by Optinose (NASDAQ: OPTN), for the treatment of chronic rhinosinusitis without nasal …

FDA Approves Optinose’s XHANCE as First Treatment for Sinusitis Without Nasal Polyps Read More
Madrigal Pharmaceuticals
Regional

Landmark FDA Approval of Rezdiffra Marks New Era for NASH Treatment

March 19, 2024March 19, 2024 - by Timothy Alexander

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc., a Montgomery County-based biopharmaceutical company, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for Rezdiffra. This game-changing medication, used in …

Landmark FDA Approval of Rezdiffra Marks New Era for NASH Treatment Read More

Venatorx Pharmaceuticals
Products and Services

FDA Requests Additional Data for Venatorx and Melinta’s Antibiotic Combination

February 28, 2024February 27, 2024 - by Timothy Alexander

MALVERN, PA — Venatorx Pharmaceuticals and Melinta Therapeutics recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning their New Drug Application (NDA) for …

FDA Requests Additional Data for Venatorx and Melinta’s Antibiotic Combination Read More
Harmony Biosciences Holdings
Regional

Harmony Biosciences’ Narcolepsy Drug for Children Gets FDA Priority Review

February 26, 2024February 25, 2024 - by Timothy Alexander

PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its supplemental New Drug Application …

Harmony Biosciences’ Narcolepsy Drug for Children Gets FDA Priority Review Read More

Johnson & Johnson
Regional

FDA Greenlights Reduced Dosing Frequency for Johnson & Johnson’s TECVAYLI

February 26, 2024February 25, 2024 - by Timothy Alexander

HORSHAM, PA — Johnson & Johnson recently announced that the U.S. Food and Drug Administration (FDA) has granted approval for a reduced dosage frequency of its drug TECVAYLI® (teclistamab-cqyv) in …

FDA Greenlights Reduced Dosing Frequency for Johnson & Johnson’s TECVAYLI Read More
Harley Jacobsen, a clinical trial participant.
Business / Research

Mural Health Champions Revolutionary Bill for Enhanced Diversity in Clinical Trials

February 16, 2024February 15, 2024 - by Timothy Alexander

BERWYN, PA — In a move to promote diversity in clinical trials, Chester County-based Mural Health has announced the “Harley Jacobsen Clinical Trial Participation Income Exemption Act,” a landmark legislation …

Mural Health Champions Revolutionary Bill for Enhanced Diversity in Clinical Trials Read More

Helius Medical Technologies
Regional

Helius Medical Technologies Advances Stroke Program with FDA Approval

February 8, 2024February 7, 2024 - by Timothy Alexander

NEWTOWN, PA — Helius Medical Technologies, Inc., a prominent player in the healthcare technology sector, has announced a significant stride towards revolutionizing stroke therapy. The company has concluded negotiations with …

Helius Medical Technologies Advances Stroke Program with FDA Approval Read More
Cabaletta Bio
Regional

FDA Awards Orphan Drug Designation to Cabaletta’s Innovative Myositis Therapy

February 3, 2024February 3, 2024 - by Timothy Alexander

PHILADELPHIA, PA — The biotech firm Cabaletta Bio, Inc. (Nasdaq: CABA) has secured an Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its investigational therapy, …

FDA Awards Orphan Drug Designation to Cabaletta’s Innovative Myositis Therapy Read More
AstraZeneca
Regional

AstraZeneca Rolls Out AIRSUPRA, a Novel Combination Therapy for Asthma

January 30, 2024January 29, 2024 - by Timothy Alexander

WILMINGTON, DE — Pharmaceutical giant AstraZeneca has announced the commercial availability of AIRSUPRA® (albuterol/budesonide) in the United States, marking a significant step forward in asthma treatment. The FDA approved AIRSUPRA …

AstraZeneca Rolls Out AIRSUPRA, a Novel Combination Therapy for Asthma Read More

Posts pagination

Previous 1 … 32 33 34 … 36 Next

Trending News

  • Traffic Stop in Wilmington Uncovers Guns, Forged Prescription Pad, and Drugs, Police Say

  • Celebrate Library Card Sign-Up Month with Free Family Fun in Exton

  • McDonald’s Robbery Suspect Turns Himself In — Another Still on the Run

  • 1 Kilo of Cocaine Seized: Man Arrested After Months-Long Police and FBI Investigation in Wilmington

  • Aclaris Therapeutics to Present at Two Investor Conferences in September

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Harice Reddick

Traffic Stop in Wilmington Uncovers Guns, Forged Prescription Pad, and Drugs, Police Say

August 29, 2025August 29, 2025

Avery Quartlebaum

McDonald’s Robbery Suspect Turns Himself In — Another Still on the Run

August 29, 2025August 29, 2025

Josue Perez

1 Kilo of Cocaine Seized: Man Arrested After Months-Long Police and FBI Investigation in Wilmington

August 29, 2025August 29, 2025

Copyright © 2025 MyChesCo.